HIGHLIGHTS
- who: Carmen Reitinger and colleagues from the Erasmus University Rotterdam, United Kingdom have published the research: Modulation of urelumab glycosylation separates immune stimulatory activity from organ toxicity, in the Journal: (JOURNAL)
- what: Immune cell infiltrates into organs the authors focused on the kidney and liver . Consistent with a model in which the severe side effects triggered by urelumab injection are mediated by the interaction of the IgG4 Fc-domain with cellular FcgRs, the study demonstrates that a deglycosylated IgG4 variant of urelumab, which has a strongly reduced ability to bind cellular FcgRs, loses its ability . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.